Expand BTAI Menu
BTAI MENU

BTAI Latest Press Releases

-- May 28, 2026 --

BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting Globe Newswire 7:00 AM

-- May 15, 2026 --

BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results Globe Newswire 7:00 AM

-- April 17, 2026 --

BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI in the At-Home Setting Globe Newswire 7:00 AM

-- April 9, 2026 --

Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PRNewswire 7:53 PM

-- April 8, 2026 --

BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions Globe Newswire 7:00 AM

-- April 1, 2026 --

BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI in the At-Home Setting Globe Newswire 7:00 AM

-- March 27, 2026 --

BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI Approval in Outpatient Setting Globe Newswire 7:00 AM

-- March 23, 2026 --

Levi & Korsinsky, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of BioXcel Therapeutics, Inc. Globe Newswire 8:00 AM

-- March 11, 2026 --

BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering Globe Newswire 4:20 PM

-- March 10, 2026 --

BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering Globe Newswire 2:36 PM

-- March 5, 2026 --

BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal Globe Newswire 7:00 AM

-- February 19, 2026 --

BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer's Dementia Globe Newswire 7:00 AM

-- February 12, 2026 --

BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI in the At-Home Setting Globe Newswire 7:00 AM
Market Data Delayed 15 Minutes